文献速递中毒与环境急症心脑血管急症

大麻与合成大麻素受体激动剂临床效应比较:2013至2020年欧洲医院急性中毒就诊的回顾性队列研究

Clinical effects of cannabis compared to synthetic cannabinoid receptor agonists (SCRAs): a retrospective cohort study of presentations with acute toxicity to European hospitals between 2013 and 2020.
PubMed 文献 · Clin Toxicol (Phila) · 2024-06-27
一句话结论单独合成大麻素受体激动剂中毒比单独大麻中毒更常出现嗜睡、昏迷、激越、癫痫和心动过缓,大麻中毒更常见心悸、胸痛、高血压、心动过速、焦虑、呕吐和头痛。

该回顾性队列研究利用欧洲药物急诊网络Plus(Euro-DEN Plus)数据,比较2013至2020年间24个欧洲国家36个中心急诊就诊的单独大麻暴露(2657例)与单独合成大麻素受体激动剂暴露(503例)的临床特征和结局。合成大麻素受体激动剂组就诊时嗜睡、昏迷、激越、癫痫和心动过缓发生率显著更高;大麻组心悸、胸痛、高血压、心动过速、焦虑、呕吐和头痛更常见。研究支持合成大麻素受体激动剂神经精神毒性更高的既往发现,并补充了大麻心血管毒性的数据。

要点

  • 单独合成大麻素受体激动剂暴露(503例)就诊时嗜睡、昏迷、激越、癫痫和心动过缓发生率显著高于单独大麻暴露(2657例)。
  • 单独大麻暴露更常见心悸、胸痛、高血压、心动过速、焦虑、呕吐和头痛。
  • 合成大麻素受体激动剂暴露更常被收入精神科病房,大麻暴露更常表现为心血管特征。
  • 研究使用Euro-DEN Plus网络2013至2020年24国36中心急诊数据,药物暴露依据自我报告。
  • 自我报告识别暴露药物是本研究局限,但既往研究显示急诊急性药物中毒中自我报告可靠。

适用人群与场景

  • 2013至2020年向欧洲24个国家36个中心急诊就诊的药物相关就诊者。
  • 分析人群为单独大麻暴露(2657例)或单独合成大麻素受体激动剂暴露(503例)的急性中毒就诊者。

红旗征与不能漏的情况

  • 合成大麻素受体激动剂暴露者就诊时出现嗜睡、昏迷、激越、癫痫或心动过缓的发生率显著更高,需警惕神经精神毒性。
  • 大麻暴露者就诊时出现心悸、胸痛、高血压、心动过速、焦虑、呕吐或头痛更常见,需关注心血管表现。

研究设计与关键结果

  • 研究类型为回顾性队列研究,数据来自欧洲药物急诊网络Plus,覆盖24个欧洲国家36个中心,2013至2020年共54314例药物相关就诊,其中单独大麻暴露2657例、单独合成大麻素受体激动剂暴露503例。
  • 合成大麻素受体激动剂组就诊时嗜睡、昏迷、激越、癫痫和心动过缓发生率显著高于大麻组(P<0.05)。
  • 大麻组心悸、胸痛、高血压、心动过速、焦虑、呕吐和头痛发生率显著高于合成大麻素受体激动剂组(P<0.05)。
  • 合成大麻素受体激动剂暴露更常被收入精神科病房,大麻暴露更常表现为心血管特征。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:自我报告用于识别就诊涉及的药物;既往研究显示急诊急性药物中毒中自我报告可靠。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「对床旁实践的改变」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Cannabis is the most common recreational drug worldwide and synthetic cannabinoid receptor agonists are currently the largest group of new psychoactive substances. The aim of this study was to compare the clinical features and outcomes of lone acute cannabis toxicity with lone acute synthetic cannabinoid receptor agonist toxicity in a large series of presentations to European emergency departments between 2013-2020.

METHODS: Self-reported drug exposure, clinical, and outcome data were extracted from the European Drug Emergencies Network Plus which is a surveillance network that records data on drug-related emergency department presentations to 36 centres in 24 European countries. Cannabis exposure was considered the control in all analyses. To compare the lone cannabis and lone synthetic cannabinoid receptor agonist groups, univariate analysis using chi squared testing was used for categorical variables and non-parametric Mann-Whitney U- testing for continuous variables. Statistical significance was defined as a P value of <0.05.

RESULTS: Between 2013-2020 there were 54,314 drug related presentations of which 2,657 were lone cannabis exposures and 503 lone synthetic cannabinoid receptor agonist exposures. Synthetic cannabinoid receptor agonist presentations had statistically significantly higher rates of drowsiness, coma, agitation, seizures and bradycardia at the time of presentation. Cannabis presentations were significantly more likely to have palpitations, chest pain, hypertension, tachycardia, anxiety, vomiting and headache.

DISCUSSION: Emergency department presentations involving lone synthetic cannabinoid receptor agonist exposures were more likely to have neuropsychiatric features and be admitted to a psychiatric ward, and lone cannabis exposures were more likely to have cardiovascular features. Previous studies have shown variability in the acute toxicity of synthetic cannabinoid receptor agonists compared with cannabis but there is little comparative data available on lone exposures. There is limited direct comparison in the current literature between lone synthetic cannabinoid receptor agonist and lone cannabis exposure, with only two previous poison centre series and two clinical series. Whilst this study is limited by self-report being used to identify the drug(s) involved in the presentations, previous studies have demonstrated that self-report is reliable in emergency department presentations with acute drug toxicity.

CONCLUSION: This study directly compares presentations with acute drug toxicity related to the lone use of cannabis or synthetic cannabinoid receptor agonists. It supports previous findings of increased neuropsychiatric toxicity from synthetic cannabinoid receptor agonists compared to cannabis and provides further data on cardiovascular toxicity in lone cannabis use.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Waters ML, Dargan PI, Yates C, et al. Clinical effects of cannabis compared to synthetic cannabinoid receptor agonists (SCRAs): a retrospective cohort study of presentations with acute toxicity to European hospitals between 2013 and 2020. Clin Toxicol (Phila). 2024. PMID: 38934347. doi:10.1080/15563650.2024.2346125

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。